COMPANY

Opus Genetics Inc

HQ: Durham, NC source · opusgtx.com ↗ · Southeast

Keywords: gene therapy bestrophinopathy Leber congenital amaurosis retinitis pigmentosa AAV small molecule Presbyopia Mydriasis Dilation Decrease in Night Vision Night Vision Complaints Autosomal-Dominant Bestrophinopathy Best Vitelliform Macular Dystrophy Vision Loss Night Vision Disorders Mesopic Vision Night Vision Loss Diabetic Retinopathy Diabetic Macular Edema NPDR - Non Proliferative Diabetic Retinopathy PDR - Proliferative Diabetic Retinopathy LCA5 Dim Light Vision Disturbances Open Angle Glaucoma Ocular Hypertension Phentolamine OPGx-BEST1 OPGx-RDH12 APX3330 AAV8.hLCA5

Location: Durham, NC · source · Oct 15, 2026

Profile checked Oct 10, 2026

$68.0MRaised (2 yrs)17Trials (company is sponsor)

Funding and NIH signals

NIH award NIH awarded $1M (SBIR Phase II 1R44EY038152-01A1, new, notice Sep 19, 2026); 2 NIH awards totaling $2.02M in the last 12 months. NIH RePORTER 1R44EY038152-01A1 (Sep 19, 2026)
Evidence (2 events)
- Sep 19, 2026 · NIH RePORTER 1R44EY038152-01A1
  Organization: OPUS GENETICS INC.; City/State: RALEIGH, NC; Project number: 1R44EY038152-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-19; FY total cost (award amount): 1004925; Administering IC: National Eye Institute; Project title: Development of OPGx-RDH12 as a gene therapy for RDH12 deficiency associated Leber congenital amaurosis (LCA); Organization type: Domestic For-Profits
- Sep 17, 2026 · NIH RePORTER 1R44EY038149-01A1
  Organization: OPUS GENETICS INC.; City/State: RALEIGH, NC; Project number: 1R44EY038149-01A1; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1012469; Administering IC: National Eye Institute; Project title: Development of OPGx-NMNAT1 as a gene therapy for NMNAT1 associated LCA.; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 1, 2026 Trial start Phase 1/Phase 2: Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD) source ↗
Feb 13, 2026 Raise Private placement: $25M (total, as published), announced Feb 13, 2026. Source: company release on GlobeNewswire. source ↗
Nov 6, 2025 Raise Follow-on offering — Registered direct: $23M (total, as published), announced Nov 6, 2025. Source: SEC filing. source ↗
Sep 25, 2025 Trial start Phase 1/Phase 2: Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) source ↗
Sep 2, 2025 Trial start Phase 3: OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity source ↗
Mar 21, 2025 Raise Follow-on offering: $20M (total, as published), announced Mar 21, 2025. Source: company release on GlobeNewswire. source ↗
Aug 15, 2024 Trial start Phase 3: Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia source ↗
Apr 1, 2024 Trial start Phase 3: Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances source ↗
Jun 15, 2023 Trial start Phase 1/Phase 2: Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients source ↗
Dec 22, 2022 Trial start Phase 3: Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia source ↗
Dec 17, 2021 Trial start Phase 3: Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects source ↗
Nov 18, 2021 Trial start Phase 3: Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3) source ↗
Apr 8, 2021 Trial start Phase 2: Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy source ↗
Feb 15, 2021 Trial start Phase 2: Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia source ↗
Dec 30, 2020 Trial start Phase 3: Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances source ↗
Nov 18, 2020 Trial start Phase 3: Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis source ↗
Aug 13, 2019 Trial start Phase 2: Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis source ↗
May 28, 2019 Trial start Phase 2: Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma source ↗
Sep 9, 2011 Trial start Phase 2: The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances source ↗
2007-08 Trial start Phase 2: Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances source ↗

Upcoming milestones

2027-08 (ESTIMATED) · Phase 3 · OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity · NCT07140783
Jun 15, 2028 (ESTIMATED) · Phase 1/Phase 2 · Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients · NCT05616793
2030-08 (ESTIMATED) · Phase 1/Phase 2 · Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB) · NCT07185256
2032-12 (ESTIMATED) · Phase 1/Phase 2 · Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD) · NCT07681778

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $68.0M. Last 2 years.

Feb 13, 2026 Private placement: $25M (total, as published), announced Feb 13, 2026. Source: company release on GlobeNewswire. source ↗
Nov 6, 2025 Follow-on offering — Registered direct: $23M (total, as published), announced Nov 6, 2025. Source: SEC filing. source ↗
Mar 21, 2025 Follow-on offering: $20M (total, as published), announced Mar 21, 2025. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 17

Record	Title	Phase	Status	Start	Primary completion
NCT01703559	The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances	Phase 2	Completed	Sep 9, 2011	Apr 16, 2012 (actual)
NCT07185256	Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)	Phase 1/Phase 2	Recruiting	Sep 25, 2025	2030-08 (estimated)
NCT07140783	OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity	Phase 3	Recruiting	Sep 2, 2025	2027-08 (estimated)
NCT06349759	Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances	Phase 3	Completed	Apr 1, 2024	Apr 17, 2025 (actual)
NCT06542497	Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia	Phase 3	Completed	Aug 15, 2024	Apr 3, 2025 (actual)
NCT07681778	Safety and Tolerability of Subretinal OPGx-RDH12-1001 for LCA-Associated Inherited Retinal Degeneration (LCA-IRD)	Phase 1/Phase 2	Not yet recruiting	Sep 1, 2026	2032-12 (estimated)
NCT05646719	Safety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia	Phase 3	Completed	Dec 22, 2022	Oct 11, 2023 (actual)
NCT04692688	Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy	Phase 2	Completed	Apr 8, 2021	Jan 25, 2023 (actual)
NCT05616793	Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients	Phase 1/Phase 2	Recruiting	Jun 15, 2023	Jun 15, 2028 (estimated)
NCT04638660	Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances	Phase 3	Completed	Dec 30, 2020	May 19, 2022 (actual)
NCT04675151	Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia	Phase 2	Completed	Feb 15, 2021	May 17, 2021 (actual)
NCT04004507	Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances	Phase 2	Completed	2007-08	2007-10 (actual)
NCT03960866	Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma	Phase 2	Completed	May 28, 2019	Sep 11, 2019 (actual)
NCT04620213	Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis	Phase 3	Completed	Nov 18, 2020	Dec 23, 2020 (actual)
NCT05223478	Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects	Phase 3	Completed	Dec 17, 2021	Apr 18, 2022 (actual)
NCT05134974	Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)	Phase 3	Completed	Nov 18, 2021	Mar 18, 2022 (actual)
NCT04024891	Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis	Phase 2	Completed	Aug 13, 2019	Sep 17, 2019 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

2024-11-07 Raise Private raise (SEC Form D): $25.8M sold; issuer “Opus Genetics, Inc.”. Verified from the SEC filing. SEC filing ↗